Drug intelligence / Profile preview

NTC chondrograft

Development stage: Phase 2
Lead developer: PrimeCell Advanced Therapy
Modality: Cell Therapies
Administration: Intraarticular, Implant

Overview

NTC chondrograft is an Advanced Therapy Medicinal Product (ATMP) developed by PrimeCell Advanced Therapy for the treatment of symptomatic knee articular cartilage defects. It is an autologous chondrocyte implantation (ACI) product consisting of the patient's own chondrocytes, which are harvested from a non-load-bearing area of the knee, expanded ex vivo, and then reimplanted into the defect site. This somatic cell therapy aims to stimulate the regeneration of hyaline-like cartilage, restoring joint function and reducing pain. It is currently being evaluated in a Phase II/III clinical trial (EudraCT: 2017-002601-35) comparing its efficacy and safety against standard arthroscopic microfracture.

Brand names: NTC chondrograft
Other names: autologous chondrocyte implantation

Beyond the preview

Go deeper on NTC chondrograft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTC chondrograft.